# psoriasis - claude-opus-4-8

- Benchmark system: raw
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 
- Completion tokens: 
- Reasoning tokens: 
- Total tokens: 
- API requests reported: 
- Elapsed seconds: 122.794
- Final benchmark system: raw; file rank 3/5; original repeat 3; model vendor: Anthropic

---
# Multidimensional Interpretation of Psoriatic Lesional Skin Transcriptomics

## 1. Overall Biological Interpretation

The transcriptomic profile reveals a coordinated tissue-level response characteristic of psoriatic lesional skin, dominated by three interconnected biological themes: **hyperproliferative epidermal differentiation**, **IL-17/IL-23 axis-driven inflammation**, and **antimicrobial defense activation**. 

The upregulated genes collectively indicate a state of keratinocyte hyperactivation with aberrant terminal differentiation (SPRR family, LCE3 family, S100A7/A8/A12), intense pro-inflammatory cytokine signaling (IL-36 family, IL-19, IL-20, IL-26), and recruitment/activation of innate immune responses (defensins, chemokines). The magnitude of effect sizes (log2FC >5-11 for multiple genes) and statistical confidence (FDR <10^-60 for top genes) reflect the profound transcriptional reprogramming in psoriatic epidermis.

The limited number of downregulated genes (BTC, CYP2W1, LINC02660, WAKMAR1, LOC genes) suggests the dominant signal is gain-of-function inflammatory activation rather than loss of homeostatic programs, though metabolic reconfiguration (CYP2W1, UGT3A2) and growth factor withdrawal (BTC) may contribute to pathological epithelial biology.

## 2. Core Biological Programs

### Program 1: IL-36/IL-17 Family Cytokine Amplification Loop
**Direction:** Strongly upregulated  
**Major supporting genes:** IL36A (log2FC=11.37), IL36G (log2FC=5.68), IL36RN (log2FC=3.01), IL19 (log2FC=7.58), IL20 (log2FC=5.67), IL26 (log2FC=4.36)  
**Pathway reference:** GO:0019221 (cytokine-mediated signaling pathway), Reactome R-HSA-448706 (Interleukin-17 signaling)  

**Interpretation:** The simultaneous upregulation of IL-36α, IL-36γ (pro-inflammatory IL-1 family cytokines specific to epithelial tissues), and IL-36RN (the endogenous antagonist, indicating feedback regulation) alongside IL-17-inducible cytokines (IL-19, IL-20, IL-26) defines a feedforward inflammatory circuit. IL-36 cytokines activate keratinocytes and dendritic cells, amplifying Th17 responses, while IL-17-induced cytokines perpetuate keratinocyte activation. This cross-talk between epithelial-derived and T cell-derived cytokines represents a central pathogenic mechanism in psoriasis.

**Evidence strength:** Strong. Multiple independent IL-36 and IL-17-pathway genes are upregulated with extreme effect sizes. This is consistent with established disease biology and supported by genetic (IL36RN mutations cause pustular psoriasis), therapeutic (IL-17 and IL-23 inhibitors are highly effective), and mechanistic evidence.

**Limitations:** The dataset cannot distinguish whether IL-36 activation is primary (keratinocyte-intrinsic) or secondary to IL-17 signaling. Cellular source cannot be definitively assigned from bulk tissue data.

### Program 2: Antimicrobial Peptide Response and Innate Immunity
**Direction:** Strongly upregulated  
**Major supporting genes:** DEFB4A/B (log2FC=11.18/11.03), DEFB103A/B (log2FC=5.76/5.75), S100A7 (log2FC=7.09), S100A7A (log2FC=9.83), S100A8 (log2FC=7.73), S100A12 (log2FC=8.33), PI3 (log2FC=9.24)  
**Pathway reference:** GO:0050832 (defense response to fungus), GO:0061844 (antimicrobial humoral immune response mediated by antimicrobial peptide), Reactome R-HSA-6798695 (Neutrophil degranulation)  

**Interpretation:** Massive upregulation of β-defensins (DEFB4A/B, DEFB103A/B), S100 alarmins (S100A7/A7A/A8/A12), and other antimicrobial proteins (PI3/elafin) reflects activation of epithelial antimicrobial defense. S100A7 and S100A8 proteins also function as chemoattractants and pro-inflammatory mediators beyond their direct antimicrobial activity. The extreme fold changes (>8-11 log2FC for multiple genes) indicate this is not subtle innate activation but a dramatic antimicrobial mobilization characteristic of psoriatic epidermis.

**Evidence strength:** Strong. Multiple functionally related but genetically independent antimicrobial genes are coordinately upregulated. S100A8/A12 proteins form calprotectin complexes and are validated biomarkers of psoriasis severity. This program is directly induced by IL-17 and IL-36 signaling (Program 1).

**Limitations:** Some genes (particularly S100A8/A12) may reflect infiltrating neutrophils or macrophages rather than keratinocyte expression. The functional relevance of antimicrobial peptides to sterile inflammation in psoriasis (vs. response to microbiome changes) remains debated.

### Program 3: Abnormal Keratinocyte Hyperproliferation and Differentiation
**Direction:** Strongly upregulated  
**Major supporting genes:** SPRR2A/B/D/E/F/G/3 (log2FC=3.99-7.31), LCE3A/D (log2FC=8.30/5.31), KRT6A (log2FC=4.30), S100A7/A8/A12, RRM2 (log2FC=2.72), CCNE1 (log2FC=2.56)  
**Pathway reference:** GO:0030216 (keratinocyte differentiation), GO:0031424 (keratinization), Reactome R-HSA-6809371 (Formation of the cornified envelope), Hallmark E2F_TARGETS  

**Interpretation:** Coordinate upregulation of small proline-rich proteins (SPRR family) and late cornified envelope proteins (LCE3 family) reflects pathological epidermal differentiation with incomplete keratinization. Unlike normal terminal differentiation, this occurs alongside active proliferation (RRM2, CCNE1 upregulation), indicating loss of normal proliferation-differentiation coupling. KRT6A (a wound/stress keratin) further marks activated keratinocyte state. This aberrant differentiation produces the characteristic scale formation and epidermal thickening (acanthosis) of psoriatic plaques.

**Evidence strength:** Moderate-strong. The SPRR/LCE signature is highly reproducible in psoriasis transcriptomics and supported by histological observations of parakeratosis and acanthosis. However, distinguishing programmed abnormal differentiation from secondary consequences of inflammation and proliferation is challenging.

**Limitations:** SPRR/LCE upregulation may be partially adaptive (barrier repair) rather than purely pathological. The causal relationship between cytokine signaling (Program 1) and differentiation defects is incompletely understood. Cell-cycle gene upregulation (RRM2, CCNE1) has modest effect sizes compared to differentiation genes, suggesting proliferation may be less transcriptionally dysregulated than differentiation.

### Program 4: Neutrophil Chemoattraction and Activation
**Direction:** Upregulated  
**Major supporting genes:** CXCR2 (log2FC=2.70), S100A8/A12 (log2FC=7.73/8.33), TCN1 (log2FC=8.04), HPSE (log2FC=2.92), IRAK2 (log2FC=2.08)  
**Pathway reference:** GO:0030593 (neutrophil chemotaxis), GO:0043312 (neutrophil degranulation), Reactome R-HSA-6798695 (Neutrophil degranulation)  

**Interpretation:** CXCR2 is the receptor for IL-8 (CXCL8) and related CXC chemokines that mediate neutrophil recruitment. TCN1 (transcobalamin-1) is a neutrophil granule protein, indicating neutrophil infiltration or activation. HPSE (heparanase) degrades extracellular matrix and releases matrix-bound cytokines, facilitating immune cell trafficking. IRAK2 amplifies TLR/IL-1R signaling in myeloid cells. Together, these genes indicate neutrophil recruitment and activation, consistent with the characteristic neutrophil microabscesses (Munro's microabscesses) in psoriatic epidermis.

**Evidence strength:** Moderate. The genes are functionally coherent, but some (S100A8/A12, TCN1) may primarily reflect neutrophil infiltration (cell composition) rather than transcriptional activation per se. CXCR2 upregulation in lesional skin could reflect keratinocyte expression (which also express CXCR2 under inflammatory conditions) or neutrophil infiltration.

**Limitations:** Bulk RNA-seq cannot distinguish between increased cell infiltration and increased per-cell gene expression. Neutrophil markers may be confounded by tissue composition. The relatively modest effect sizes for some genes (CXCR2, HPSE, IRAK2) compared to keratinocyte-specific genes suggest neutrophil signals are real but not dominant in whole-tissue samples.

### Program 5: Lipid Metabolism and Barrier Remodeling
**Direction:** Mixed (primarily upregulated)  
**Major supporting genes:** FABP5 (log2FC=3.64), AKR1B10/15 (log2FC=6.27/5.23), PLA2G4D/E (log2FC=4.61/2.47), downregulated: CYP2W1 (log2FC=-4.70), UGT3A2 (log2FC=-4.59)  
**Pathway reference:** GO:0006629 (lipid metabolic process), GO:0055114 (oxidation-reduction process), Reactome R-HSA-556833 (Metabolism of lipids)  

**Interpretation:** FABP5 (fatty acid binding protein 5) regulates lipid trafficking and has been shown to promote keratinocyte proliferation and psoriasis-like inflammation in mouse models. AKR1B10/15 (aldo-keto reductases) metabolize lipid aldehydes and prostaglandins, potentially modulating inflammatory lipid mediators. PLA2G4D/E (phospholipase A2 family) release arachidonic acid for eicosanoid synthesis. Downregulation of CYP2W1 and UGT3A2 (xenobiotic/lipid metabolizing enzymes) suggests metabolic rewiring. This pattern indicates altered lipid metabolism affecting both barrier function and inflammatory signaling.

**Evidence strength:** Moderate. The genes are functionally related but represent diverse lipid pathways. FABP5 has direct mechanistic links to psoriasis pathogenesis (keratinocyte activation, dendritic cell function). However, the functional consequences of AKR1B10/15 upregulation and CYP2W1/UGT3A2 downregulation in psoriasis are less established.

**Limitations:** Lipid metabolism changes may be secondary to inflammation rather than primary drivers. The specific lipid species and metabolites affected cannot be determined from transcriptomics alone. Some changes may reflect adaptive barrier repair rather than pathological processes.

## 3. Key Genes and Interaction Modules

### Gene 1: IL36A (log2FC=11.37, FDR=1.65×10^-98)
**Role:** Central driver of epithelial-immune amplification loop. IL-36α activates keratinocytes and dendritic cells, inducing chemokines, antimicrobial peptides, and additional cytokines. It signals through IL-36R (IL1RL2) and recruits the same signaling adapters (MyD88, IRAK) as IL-1.

**Relationship to core programs:** Primary driver of Program 1 (cytokine amplification) and upstream activator of Program 2 (antimicrobial response) and Program 3 (keratinocyte activation).

**Interactions:** IL-36α induces expression of CXCL8, CCL20, and other chemokines (regulatory interaction) and synergizes with IL-17 signaling through convergence on NF-κB and AP-1 transcription factors (pathway co-membership). IL36RN (also upregulated) functions as a naturally occurring competitive inhibitor of IL-36 signaling (direct physical interaction at receptor level).

### Gene 2: DEFB4A/B (log2FC=11.18/11.03, FDR ~10^-69)
**Role:** Human β-defensin 2 (hBD-2) is a major antimicrobial peptide with chemotactic activity for memory T cells and immature dendritic cells through CCR6. Beyond antimicrobial function, it acts as a damage-associated molecular pattern (DAMP) linking innate and adaptive immunity.

**Relationship to core programs:** Major component of Program 2 (antimicrobial defense) and functional link between Programs 1 and 4 (cytokine induction → defensin expression → immune cell recruitment).

**Interactions:** DEFB4 expression is directly induced by IL-17A, IL-22, and IL-36 cytokines (regulatory interaction). DEFB4 protein chemotactically attracts CCR6+ cells including Th17 cells (indirect relationship through chemokine receptor signaling), potentially creating positive feedback.

### Gene 3: S100A7/S100A7A (log2FC=7.09/9.83, FDR ~10^-62 to 10^-65)
**Role:** Psoriasin (S100A7) and koebnerisin (S100A7A) are Ca²⁺-binding proteins with antimicrobial activity, chemotactic properties (via RAGE receptor), and roles in keratinocyte differentiation. S100A7A is particularly enriched in psoriatic skin.

**Relationship to core programs:** Key components of Program 2 (antimicrobial defense) and Program 3 (keratinocyte differentiation). S100A7 has been proposed as both consequence and contributor to psoriatic inflammation.

**Interactions:** S100A7 binds to RAGE (receptor for advanced glycation end products) and activates NF-κB signaling (direct protein-receptor interaction). Co-expressed with other S100 family members (S100A8/A9 form calprotectin heterodimers through direct physical interaction; S100A7/A7A may have co-expression relationship but direct interaction unclear).

### Gene 4: SPRR2 family (log2FC=3.99-7.31, multiple family members)
**Role:** Small proline-rich proteins are crosslinked into the cornified envelope during terminal keratinocyte differentiation. In psoriasis, their expression is expanded to suprabasal layers and occurs alongside proliferation, indicating aberrant differentiation.

**Relationship to core programs:** Defining markers of Program 3 (abnormal differentiation). The coordinated upregulation of multiple SPRR2 paralogs (A/B/D/E/F/G) indicates activation of a differentiation program rather than isolated gene effects.

**Interactions:** SPRR proteins are substrates for transglutaminases (TGMs) that catalyze crosslinking (enzyme-substrate relationship, not direct interaction per se). They are part of the epidermal differentiation complex (EDC) gene cluster on chromosome 1q21, suggesting coordinated transcriptional regulation (genomic co-location and potential shared enhancers, not protein-protein interaction).

### Gene 5: FABP5 (log2FC=3.64, FDR=2.76×10^-81)
**Role:** Fatty acid binding protein 5 shuttles lipids to nuclear receptors (particularly PPARβ/δ) to regulate transcription. FABP5 promotes keratinocyte proliferation and psoriasis-like inflammation. Genetic deletion of FABP5 reduces psoriasiform inflammation in mouse models.

**Relationship to core programs:** Key component of Program 5 (lipid metabolism) with mechanistic links to Program 3 (keratinocyte proliferation/differentiation).

**Interactions:** FABP5 binds fatty acids (direct ligand-binding) and delivers them to PPARβ/δ nuclear receptor (direct protein-facilitated lipid transfer). PPARβ/δ activation regulates keratinocyte proliferation and inflammatory gene expression (regulatory interaction at transcriptional level).

### Gene 6: S100A12 (log2FC=8.33, FDR=7.94×10^-97)
**Role:** Calgranulin C, primarily expressed in neutrophils and monocytes, functions as an alarmin by binding RAGE and TLR4. Elevated in serum and skin of psoriasis patients.

**Relationship to core programs:** Component of Program 2 (innate immunity) and marker of Program 4 (neutrophil infiltration/activation).

**Interactions:** S100A12 binds to RAGE and TLR4 receptors (direct protein-receptor interactions) to activate inflammatory signaling. Unlike S100A8/A9 which heterodimerize, S100A12 functions as a homodimer (direct physical interaction between S100A12 monomers).

### Module 7: IL-36/IL-36RN Axis
**Genes:** IL36A, IL36G, IL36RN  
**Role:** IL-36α and IL-36γ are agonists; IL-36RN is the receptor antagonist. The ratio of agonist to antagonist determines net IL-36 pathway activation. All three are upregulated, but agonists show higher fold changes (11.37 and 5.68 vs. 3.01), suggesting net pathway activation despite feedback antagonist induction.

**Relationship to core programs:** Central to Program 1. This module represents the balance between pro-inflammatory signals and endogenous negative regulation.

**Interactions:** IL36A, IL36G, and IL36RN compete for binding to IL-36R (IL1RL2) (direct physical interaction with shared receptor). Agonist binding recruits IL-1RAcP co-receptor and activates MyD88-dependent signaling; antagonist binding blocks receptor without signaling.

### Module 8: Aldo-Keto Reductase Family (AKR1B10, AKR1B15)
**Role:** These enzymes reduce aldehydes and ketones, including products of lipid peroxidation and retinaldehyde (precursor to retinoic acid). AKR1B10 is induced by inflammation and may modulate retinoic acid signaling and oxidative stress responses.

**Relationship to core programs:** Components of Program 5 (lipid/retinoid metabolism). May influence Program 3 through effects on retinoic acid (retinoids regulate keratinocyte differentiation).

**Interactions:** AKR1B10 and AKR1B15 share substrate specificity and likely have overlapping functions (pathway co-membership, not direct interaction). They metabolize retinaldehyde, potentially competing with retinaldehyde dehydrogenases (ALDHs) that produce retinoic acid (indirect relationship through competing metabolic pathways).

### Gene 9: KYNU (log2FC=4.42, FDR=2.00×10^-91)
**Role:** Kynureninase catalyzes steps in tryptophan degradation via the kynurenine pathway, producing metabolites with immunomodulatory effects. Increased kynurenine pathway activity has been reported in psoriasis and may influence T cell responses.

**Relationship to core programs:** Potential metabolic contributor to inflammatory environment, not clearly assigned to major programs above. May represent a metabolic reprogramming program not fully captured.

**Interactions:** KYNU functions downstream of IDO1 and TDO2 (tryptophan dioxygenases) in the kynurenine pathway (pathway co-membership, sequential enzymatic steps). Kynurenine metabolites can activate the aryl hydrocarbon receptor (AhR), which regulates immune cell differentiation and cytokine production (indirect relationship through metabolite-receptor signaling).

### Gene 10: CD274 (PD-L1) (log2FC=3.44, FDR=1.82×10^-63)
**Role:** Programmed death ligand 1 (PD-L1) is an immune checkpoint molecule that inhibits T cell activation upon binding PD-1. Its upregulation may represent a negative feedback mechanism to limit T cell-mediated inflammation, though it is insufficient to resolve psoriatic inflammation.

**Relationship to core programs:** Not a major component of the five core programs but represents an important immunoregulatory mechanism. May reflect attempted (but inadequate) inflammatory resolution.

**Interactions:** CD274 protein on keratinocytes or antigen-presenting cells binds PD-1 on T cells (direct protein-receptor interaction), delivering inhibitory signals. CD274 expression is induced by IFN-γ and other inflammatory cytokines (regulatory interaction). The modest fold change (3.44) relative to pro-inflammatory genes suggests feedback regulation is overwhelmed.

## 4. Validation Priorities

### Priority 1: IL-36 Blockade as Therapeutic Target
**Classification:** Therapeutic target  
**Rationale:** IL-36α shows the highest fold change (11.37) and FDR (1.65×10^-98) among all genes, is mechanistically positioned as an amplifier of psoriatic inflammation, and links epithelial and immune responses.

**Current dataset evidence:** Extreme upregulation of IL36A and IL36G with inadequate compensatory IL36RN upregulation indicates net pathway activation. Multiple downstream targets (antimicrobial peptides, chemokines) are also upregulated, consistent with IL-36-driven signaling.

**External evidence supporting:**
- Genetic: IL36RN loss-of-function mutations cause generalized pustular psoriasis (GPP)
- Preclinical: IL-36R-deficient mice are protected from psoriasiform inflammation
- Clinical: Spesolimab (anti-IL-36R antibody) is approved for GPP and shows efficacy in palmoplantar pustulosis
- Mechanistic: IL-36 induces chemokines (CXCL1, CXCL8, CCL20), antimicrobial peptides, and synergizes with IL-17

**External evidence against:**
- IL-36 blockade efficacy in chronic plaque psoriasis (the most common form) is not yet definitively established
- IL-36 may be more critical in pustular forms than plaque psoriasis

**Next validation step:** Examine IL-36 pathway activation across psoriasis subtypes (plaque vs. pustular) and correlate IL36A expression with clinical severity and treatment response. Test whether IL-36 blockade reduces downstream inflammatory markers (S100A7, DEFB4, CXCR2) in ex vivo skin models or clinical trials.

**Evidence status:** Supported hypothesis for pustular forms; exploratory hypothesis for plaque psoriasis.

### Priority 2: Cell Composition vs. Transcriptional Activation for Neutrophil/Myeloid Signatures
**Classification:** Confounding or composition check  
**Rationale:** Many highly upregulated genes (S100A8/A12, TCN1) are primarily expressed in neutrophils and macrophages. The current bulk RNA-seq cannot distinguish whether their upregulation reflects cellular infiltration or transcriptional activation within resident cells.

**Current dataset evidence:** Strong upregulation of myeloid-associated genes alongside keratinocyte-specific genes. Some genes (CXCR2, IRAK2) could be expressed in multiple cell types.

**External evidence:**
- Histological evidence confirms neutrophil infiltration (Munro's microabscesses) and macrophage accumulation in psoriatic skin
- Single-cell RNA-seq studies show both infiltrating myeloid cells and activation of keratinocyte inflammatory programs
- S100A7/A7A are keratinocyte-derived, while S100A8/A12 are primarily myeloid-derived

**Next validation step:** Perform cell-type deconvolution using established signatures or orthogonal validation with single-cell RNA-seq. Immunohistochemistry or in situ hybridization can localize high-expressing genes to specific cell layers/types. Compare lesional vs. non-lesional skin from the same patients to control for systemic factors.

**Expected outcome:** Likely to find that extreme upregulation of DEFB4, S100A7, SPRR genes reflects keratinocyte activation, while S100A8/A12 primarily reflects neutrophil/macrophage infiltration. This distinction is critical for interpreting mechanism and targeting therapies.

**Evidence status:** Established evidence for cellular infiltration; validation needed to quantify contribution to transcriptomic signal.

### Priority 3: FABP5-PPARβ/δ Axis as Targetable Lipid Signaling Node
**Classification:** Mechanistic hypothesis and therapeutic target  
**Rationale:** FABP5 is upregulated (log2FC=3.64, FDR=2.76×10^-81) and has mechanistic evidence linking it to keratinocyte hyperproliferation and psoriatic inflammation through PPARβ/δ signaling.

**Current dataset evidence:** FABP5 upregulation occurs alongside other lipid metabolism changes (AKR1B10/15, PLA2G4D/E upregulated; CYP2W1, UGT3A2 downregulated). Coordinate lipid pathway dysregulation suggests functional relevance rather than isolated gene effect.

**External evidence supporting:**
- Fabp5-knockout mice show reduced psoriasiform inflammation in imiquimod models
- FABP5 delivers endogenous ligands to PPARβ/δ, promoting keratinocyte proliferation
- PPARβ/δ antagonists reduce inflammation in psoriasis models
- FABP5 is elevated in human psoriatic skin and correlates with disease activity

**External evidence complicating:**
- PPARβ/δ has complex context-dependent effects (can be pro- or anti-inflammatory)
- No validated FABP5 inhibitors exist for clinical use
- Lipid metabolism is interconnected; targeting one node may have unpredictable effects

**Next validation step:** 
1. Mechanistic: Test whether FABP5 inhibition (genetic or chemical) reduces IL-36 or IL-17-induced inflammatory responses in primary human keratinocytes
2. Translational: Correlate FABP5 expression with disease severity and monitor whether successful treatment (biologics) reduces FABP5 expression
3. Target validation: Develop or test specific FABP5 inhibitors for preclinical psoriasis models

**Evidence status:** Supported hypothesis based on mechanistic studies; requires target validation for therapeutic development.

### Priority 4: IL-36/Antimicrobial Peptide/Th17 Circuit as Network Hypothesis
**Classification:** Interaction/network hypothesis  
**Rationale:** The data suggest a multi-node positive feedback circuit: IL-36 → antimicrobial peptides (DEFB4, S100A7) → CCR6+ Th17 cell recruitment → IL-17 production → keratinocyte activation and more IL-36. Testing this network hypothesis could identify optimal combination therapy targets.

**Current dataset evidence:** Simultaneous upregulation of IL-36 cytokines, antimicrobial peptides with chemotactic function (DEFB4, S100A7), IL-17-induced genes (IL-19, IL-20), and Th17-recruiting chemokine receptor (implied by DEFB4/S100A7 which attract CCR6+ cells).

**External evidence supporting:**
- IL-36 induces DEFB4 and S100A7 in keratinocytes (regulatory interaction)
- DEFB4 and S100A7 attract CCR6+ Th17 c
